In the current study, we used human PNPLA3 mutant iPSC–derived hepatocytes to effectively model the onset of NAFLD and provide a platform for the discovery of pathways involved in lipid accumulation in the variant background. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.